STAT3 activation leads to the inhibition of apoptosis and tumor progression in TNBC, and its dysfunction induces cell death in vitro and in vivo, implicating STAT3 as an attractive therapeutic target [24–26]. The gene discussed is STAT3; the disease is neoplasm.